Federally Funded Clinical Trials

Federally Funded Clinical Trials

Our research sites continue to participate in Federally-funded research through NRG Oncology.  The following protocols are currently open to accrual.  Please visit the CTSU members' website for full information about these protocols.


NSABP B-51

Protocol Activation (Date Opened to Accrual): 08/22/2013

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

ClinicalTrials.gov Identifier: NCT01872975

 

NSABP B-52

Protocol Activation (Closed to Accrual)

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

ClinicalTrials.gov Identifier: NCT02003209


NSABP B-53/SWOG S1207

Protocol Activation (Date Opened to Accrual): 09/03/2013

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

e3 Breast Cancer Study - evaluating everolimus with endocrine therapy

ClinicalTrials.gov Identifier: NCT01674140

 

NSABP B-55/BIG 6-13

Protocol Activation (Date Opened to Accrual): 07/03/2014

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

ClinicalTrials.gov Identifier: NCT02032823

 

NRG - BR003

Protocol Activation (Date Opened to Accrual): 06/26/2015

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

ClinicalTrials.gov Identifier: NCT02488967


NRG - GI002

Protocol Activation (Date Opened to Accrual): 10/12/2016

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

ClinicalTrials.gov Identifier: NCT02921256


NRG - BR005

Protocol Activation (Date Opened to Accrual): 04/13/2017 

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery

ClinicalTrials.gov Identifier: NCT03188393